Braun Stacey Associates Inc. increased its stake in shares of Pfizer (NYSE:PFE) by 15.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 469,426 shares of the biopharmaceutical company’s stock after acquiring an additional 62,865 shares during the period. Pfizer comprises approximately 1.1% of Braun Stacey Associates Inc.’s investment portfolio, making the stock its 26th largest holding. Braun Stacey Associates Inc.’s holdings in Pfizer were worth $17,003,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Pfizer by 4.4% during the third quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock worth $2,136,189,000 after acquiring an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. increased its position in Pfizer by 0.9% during the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after buying an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Pfizer by 4.8% during the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after buying an additional 2,028,313 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in Pfizer by 3.6% during the fourth quarter. Fisher Asset Management LLC now owns 36,372,349 shares of the biopharmaceutical company’s stock worth $1,317,407,000 after buying an additional 1,251,550 shares during the last quarter. Institutional investors and hedge funds own 71.20% of the company’s stock.
A number of equities analysts have weighed in on PFE shares. Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, January 30th. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a research report on Wednesday, January 17th. Morgan Stanley set a $41.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. JPMorgan Chase reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, January 30th. Finally, BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Friday, December 8th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the stock. Pfizer has an average rating of “Hold” and an average price target of $39.25.
Pfizer stock opened at $35.17 on Friday. Pfizer has a 12 month low of $31.67 and a 12 month high of $39.43. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. The company has a market capitalization of $215,077.02, a PE ratio of 13.27, a PEG ratio of 1.80 and a beta of 0.90.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter in the prior year, the business earned $0.47 earnings per share. The firm’s revenue for the quarter was up .6% on a year-over-year basis. analysts anticipate that Pfizer will post 2.96 EPS for the current year.
Pfizer announced that its Board of Directors has initiated a share buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.